Core Insights - Complement drugs are specifically designed to treat diseases related to abnormal activation or suppression of the complement system, with a complex development history that faced significant challenges until the first drug, Soliris, was approved in 2007 [1][4] - The market for complement drugs is expanding rapidly, with a projected global market size of $8.179 billion in 2024, reflecting a year-on-year growth of 23.4%, primarily driven by advancements in treatment for eye diseases [1][6] - The leading complement drugs in the market are AstraZeneca's C5 antibodies, Soliris and Ultomiris, which together are expected to account for 79.6% of total sales in 2024 [1][6][7] Industry Overview - The complement drug industry has evolved to include over ten approved drugs, utilizing various forms such as monoclonal antibodies, small molecule inhibitors, cyclic peptides, and nucleic acid aptamers, indicating a diverse technological landscape [1][4] - The expansion of indications from rare blood diseases to more common conditions signifies a maturation in the development of complement drugs, with ongoing research opening new therapeutic areas [1][4][8] Market Dynamics - The sales of Ultomiris are projected to grow significantly, from $339 million in 2019 to $3.924 billion in 2024, surpassing Soliris, which is expected to see a decline in sales by 17.7% to $2.588 billion in 2024 [7] - Domestic companies such as Heng Rui Medicine and Hai Si Ke are actively entering the complement drug market, with over ten clinical trials registered in China, primarily focusing on IgA nephropathy [1][8] Future Trends - The competition in the complement drug market is expected to intensify with the introduction of more drugs, emphasizing technological innovation and cost reduction to enhance accessibility [8] - There is a growing focus on multi-target and combination therapy strategies, which may improve treatment efficacy and reduce side effects, as well as an expansion of applications to include more rare and autoimmune diseases [8]